DSM B.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 nov 2013 - 06:08
Statutaire naam
DSM B.V.
Titel
Royal DSM and JLL create leading pharma services company in USD 2.6 bn transaction; Global CDMO company combines DSM Pharmaceutical Products and Patheon
Bericht
JLL Partners ("JLL"), a leading middle-market private equity firm, and Royal DSM, the global Life Sciences and Materials Sciences company, today announced the creation of a new company, which will be a leading global contract development and manufacturing organization (CDMO) for the pharmaceutical industry with anticipated sales of around USD 2 billion. It will be 51% owned by JLL and 49% by DSM.
The name of the company (provisionally called NewCo) will be announced in the coming months. NewCo will be formed by combining DSM's business group DSM Pharmaceutical Products ("DPP") with Patheon Inc. (TSX: PTI) ("Patheon"), after a successful completion of the transaction described below. NewCo will be a leading global contract development and manufacturing organization with anticipated 2014 sales of about USD 2 billion (pro-forma) and a strong EBITDA and operational cash flow.
Datum laatste update: 01 september 2024